Wegovy coverage shifts to maintenance

Wegovy is turning into a maintenance story, not a miracle-before-and-after story. That shift got sharper in April, when the FDA cleared Wegovy HD — a new 7.2 mg semaglutide dose for weight loss and long-term maintenance of weight loss in certain adults. At the same time, the current prescribing materials now frame Wegovy as a chronic treatment with multiple maintenance doses, not a quick intervention you finish and forget. ### What changed in the actual drug? The biggest concrete update is Wegovy HD. The FDA approved the higher 7.2 mg injection in April 2026, and Novo Nordisk’s prescribing materials now show a ladder of maintenance options rather than one fixed end point. Patients can stay at 1.7 mg, 2.4 mg, or move higher if they tolerate treatment and still need more weight reduction. That matters because “maintenance” is now built into the product design, not just something clinicians talk about afterward. (fda.gov) ### Why does maintenance suddenly feel like the whole story? Because the older dream — lose a lot of weight, stop the drug, keep the result — never held up very well. In the STEP 1 extension, people who stopped semaglutide regained a large share of the lost weight over the following year. That result has hung over the whole category ever since. It pushed obesity specialists toward a more blunt framing: for many patients, GLP-1 treatment behaves more like blood-pressure medicine than a one-time reset. (fda.gov) ### Does staying on it actually hold the loss? Mostly, yes — while treatment continues. In the 104-week STEP 5 trial, semaglutide produced sustained weight loss over two years, which is why the maintenance framing has become harder to ignore. The point is not that everyone responds the same way. They do not. But the broad pattern is clear: continued treatment supports continued weight control much better than stopping and hoping behavior alone can do the rest. (nature.com) ### So why are people talking so much about muscle? Because weight loss is not automatically the same thing as better body composition. Obesity-medicine groups and recent clinical commentary have put more emphasis on preserving lean mass through resistance training, protein intake, and follow-up instead of treating the drug like a stand-alone fix. The concern is not that GLP-1 drugs uniquely “eat muscle.” The concern is that any substantial weight loss can reduce lean mass, and fast appetite suppression can make that easier to miss. (nature.com) ### What else has to be monitored long term? Mostly the boring but important stuff — gastrointestinal side effects, gallbladder issues, pancreatitis warnings, kidney risk in some settings, and tolerability over time. Wegovy’s label still carries the boxed thyroid C-cell tumor warning based on rodent findings, and the FDA’s review history for semaglutide has emphasized long-term safety follow-up for serious gastrointestinal and other adverse events. (academy.obesitymedicine.org) Chronic-use framing brings chronic monitoring with it. ### Where do oral GLP-1s fit in? They make the category look even more like long-run obesity management. The newest Wegovy label materials now refer to both injection and tablet forms, which lowers the psychological barrier for some patients and widens the maintenance conversation beyond weekly shots. More formats usually mean more people trying treatment — and more attention on what happens in year 2, not just month 3. (wegovy.com) ### Why does this matter beyond one drug? Because the whole obesity-drug market is maturing. Early coverage obsessed over dramatic percentage drops. Now the harder questions are winning: who keeps the weight off, who regains, who tolerates therapy, who preserves strength, and who can actually stay on treatment. That is a more medical, less viral frame — but it is also the one that decides whether these drugs change health for five years instead of five months. (accessdata.fda.gov) ### Bottom line? Wegovy did not stop being a weight-loss drug. But the center of gravity moved. The real story now is maintenance — dose selection, side-effect management, muscle preservation, and the uncomfortable fact that for many patients, the treatment only works as long as the treatment continues. (fda.gov) (obesitymedicine.org)